New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 1 of 8
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07423546
Helping Adults With Obsessive-Compulsive Disorder Succeed at Work
NCT07124780
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
NCT05999240
Exercise and Olanzapine-samidorphan
NCT06740890
Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)
NCT05477901
Effects of rTMS on Food Choice in Anorexia Nervosa
NCT05918835
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Relapse Prevention and Changing Habits in Anorexia Nervosa
NCT04810624
Computer - Based Treatment for Social Anxiety Disorder
NCT04663724
Clinical Trials of Multivalent Opioid Vaccine Components
NCT04458545
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
NCT04084860
Scaling up e-Connect in Juvenile Probation Settings
NCT05541926
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
NCT05690503
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
NCT05712707
Facilitating Opioid Care Connections
NCT04216719
Facilitating Rapid Naltrexone Initiation
NCT03345173
Sleep Interventions and Neurocognitive Outcomes
NCT05987007
Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems
NCT07594730
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
NCT06518941
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts
NCT07139106
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
NCT05974202
RCT of a Brief Video Intervention Targeting Peer Inclusion to Reduce Depression-related Stigma in Adolescents
NCT06360107
Reducing Stigma and Increasing Treatment Seeking Intentions Among Adolescents
NCT06222528
Reducing Depression Self-stigma and Increasing Treatment Seeking Intentions Among Youth
NCT06172075
A Study of SPG Block for Opioid Withdrawal
NCT04946656
Reducing Self-stigma Using Brief Video Intervention
NCT05878470
Investigation of TEST (Transcranial Electric Stimulation Therapy) for Chronic Pain
NCT05113563
Partners in School: Promoting Continuity Across Home and School
NCT05154981
A Trial of Guanfacine-er for Cannabis Use Disorder
NCT05273567
Pilot Study Adapting EAT-PTSD for Anxious Youth
NCT05298397
Boricua Youth Study COVID-19 Coping Intervention Study
NCT05444881
Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities
NCT04958798
Impact of Telehealth on Engagement in Psychotherapy and/or Medication Treatment
NCT04931927
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
NCT05114460
Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing
NCT04650217
Cognitive Functioning in Opioid Use Disorder
NCT05001789
Repeated Cannabis Administration on Experimental Pain and Abuse Liability
NCT04576507
Leveraging Social Networks to Increase COVID-19 Testing Uptake
NCT04873401
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
NCT04762537
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
NCT04697693
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
NCT04656301
1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
NCT04493320
Valacyclovir for Mild Cognitive Impairment
NCT04710030
Mechanisms of Emotion Regulation Underlying Successful CBT in Depression
NCT04328103
Ketamine Treatment Effects on Synaptic Plasticity in Depression
NCT04091971
Using mHealth to Optimize Pharmacotherapy Regimens
NCT04248517
Use of Antiretroviral (ARV) Drug Levels in Dried Blood Spots (DBS) to Assess and Manage ART Adherence in South Africa
NCT04333498
Treating Self Injurious Behavior: A Novel Brain Stimulation Approach
NCT04244786
Eye Tracking as a Biomarker of Cannabis Effects
NCT04100590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.